Share

March 30, 2021; 96 (13) Resident & Fellow Section

Teaching NeuroImages: Parkinsonism Secondary to a Metastatic Lesion Involving the Substantia Nigra

Kosei Hirata, Takanori Yokota, Yoshiharu Miura
First published November 9, 2020, DOI: https://doi.org/10.1212/WNL.0000000000011162
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
676

Share

Article Information

vol. 96 no. 13 e1800-e1801
DOI: 
https://doi.org/10.1212/WNL.0000000000011162
PubMed: 
33168703
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published November 9, 2020.

Article Versions

Copyright & Usage: 
© 2020 American Academy of Neurology

Author Disclosures

    1. Kosei Hirata, MD,
    2. Takanori Yokota, MD, PhD and
    3. Yoshiharu Miura, MD, PhD
  1. Kosei Hirata, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Takanori Yokota, MD, PhD and
    3. Scientific Advisory Boards:

    1. Biogen Japan Ltd.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. He has received speaker's honoraria from (1) Kyowa Kirin Co., Ltd., (2) Soyaku Yakuri Forum, (3) Tokyo University of Science, (4) Teijin Pharma Limited, (5) Takeda Pharmaceutical Company Limited, (6) Mitsubishi Tanabe Pharma Corporation, (7) Daiichi Sankyo Company, Limited, (8) Nihon Medi-Physics Co., Ltd., (9) Otsuka Pharmaceutical Co., Ltd., (10) CSL Behring K.K., (11) The Academy of Pharmaceutical Science and Technology, Japan, (12) Kyoto Prefectural University of Medicine, (13) Kawasaki Institute of Industrial Promotion, (14) Nikkei Business Publications, Inc., (15) Astellas Pharma Inc., (16) Biogen Japan Ltd., and (17) Tokyo Metropolitan Institute of Medical Science.

    Editorial Boards:

    1. NONE

    Patents:

    1. (1) heteroduplex nucleotide

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Sumitomo Dainippon Pharma Co., Ltd., (2) Teijin Pharma Limited, (3) Rena Therapeutics, Inc., and (4) Braizon Therapeutics, Inc.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Nihon Medi-Physics Co., Ltd., (2) Nihon Pharmaceutical Co., LTD., (3) Mitsubishi Tanabe Pharma Corporation, (4) Eli Lilly Japan K.K., (5) Shionogi & Co., Ltd., (6) Eisai Co., Ltd., (7) MSD K.K., (8) Sumitomo Dainippon Pharma Co., Ltd., (9) Daiichi Sankyo Company, Limited, (10) Kyowa Kirin Co., Ltd., (11) Teijin Pharma Limited, (12) Takeda Pharmaceutical Company Limited, (13) Otsuka Pharmaceutical Co., Ltd., (14) CSL Behring K.K., (15) Astellas Pharma Inc., (16) Japan Blood Products Organization, (17) Novartis Pharma K.K., (18) Pfizer Japan, Inc., (19) FP Pharmaceutical Corporation, and (20) Sanofi K.K.

    Research Support, Government Entities:

    1. (1) Japan Science and Technology Agency, JPMJCR12L4, Principal Investigator, 2012-2019, (2) Japan Science and Technology Agency, No grant ＃, Co-Investigator, 2013-2021, (3) Japan Agency for Medical Research and Development, 18aｍ0301003, Principal Investigator, 2012-2019, (4) Japan Agency for Medical Research and Development, 20dｍ0107063, Principal Investigator, 2016-2021, (5) Japan Agency for Medical Research and Development, 20am0401006, Principal Investigator, 2019-2024, (6) Japan Agency for Medical Research and Development, 19lk1403008, Co-Investigator, 2017-2020, (7) Japan Agency for Medical Research and Development, 19ek0610013, Co-Investigator, 2017-2020, (8) Japan Agency for Medical Research and Development, 20ek0109301, Co-Investigator, 2018-2020, (9) Japan Agency for Medical Research and Development, 20ek0109302, Co-Investigator, 2018-2021, (10) Japan Agency for Medical Research and Development, 20mk0101122, Co-Investigator, 2018-2021, (11) Japan Agency for Medical Research and Development, 19ek0109422, Co-Investigator, 2019-2021, (12) Japan Agency for Medical Research and Development, 20ek0109459, Co-Investigator, 2020-2022, (13) Japan Agency for Medical Research and Development, 18ek0210054, Co-Investigator, 2016-2019, (14) New Energy and Industrial Technology Development Organization, 18ae0101016, Co-Investigator, 2014-2018, (15) Japan Society for the Promotion of Science, 17H06109, Principal Investigator, 2017-2021, (16) Japan Society for the Promotion of Science, 19H01016, Co-Investigator, 2019-2021, (17) Ministry of Health, Labour and Welfare of Japan, No grant ＃, Co-Investigator, 2017-2019, (18) Ministry of Health, Labour and Welfare of Japan, 20FC1030, Co-Investigator, 2020-2022

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. (1) heteroduplex nucleotide, Astellas Pharma Inc., 2018, (2) heteroduplex nucleotide, Rena Therapeutics Inc, 2019, 2020, (3) heteroduplex nucleotide, Takeda Pharmaceutical Co.,Ltd., 2020

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Yoshiharu Miura, MD, PhD
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (K.H., Y.M.), Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; and Department of Neurology and Neurological Science (K.H., T.Y.), Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan.
  1. Correspondence
    Dr. Hirata k-hirata.nuro{at}tmd.ac.jp
View Full Text

Article usage

Article usage: November 2020 to December 2022

AbstractFullPdfSource
Nov 202000137Highwire
Dec 20200033Highwire
Jan 20210020Highwire
Feb 20210021Highwire
Mar 2021043857Highwire
Apr 20211912115Highwire
May 202109233Highwire
Jun 202106616Highwire
Jul 202104625Highwire
Aug 202109920Highwire
Sep 202116717Highwire
Oct 202105732Highwire
Nov 202105828Highwire
Dec 202103012Highwire
Jan 202202518Highwire
Feb 20220252Highwire
Mar 20220247Highwire
Apr 202202516Highwire
May 202203312Highwire
Jun 20220197Highwire
Jul 20220217Highwire
Aug 202201711Highwire
Sep 202201512Highwire
Oct 20220278Highwire
Nov 20220208Highwire
Dec 20220122Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me